Newsletter sign up



Copyright 2017
Terms & Conditions


Gerhardt Attard, MD, Ph.D on Prostate Cancer at the European Cancer Congress 2013

In this interview:

  • Enzalutamide monotherapy in hormone naïve prostate cancer (Smith M)
  • Proof-of concept study of androgen receptor antagonist ODM-201 (Fizazi K)
  • Degarelix versus luteinising hormone-releasing hormone agonists (Tombal B)

For more information:

Abstracts: Genitourinary Malignancies – Prostate

  • Abstract: # 2852. Authors and title: Smith M, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Baskin-Bey E, Perabo F, Phung D, Tombal H. Enzalutamide (ENZA) monotherapy in hormone naive prostate cancer (HNPC): Complete analysis of a phase 2 study [Abstract Link]
  • Abstract: # 2853 Authors and title: Fizazi K, Bono P, Jones RH, Kataja V, James N, Garcia J, Protheroe A, Vuorela A, Mattila L, Mustonen MVJ. An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC) [Abstract Link]
  • Abstract: # 2855 Authors and title: Tombal B, Miller K, De Reijke TM, Persson BE. Degarelix versus luteinising hormone-releasing hormone (LHRH) agonists: Safety outcomes from six comparative randomised clinical trials [Abstract Link]

This interview is produced in collaboration with



 

Copyright © 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.